Mumbai, June 8: Sun Pharmaceutical Industries today said it would focus on dermatology as the fourth engine of growth for its over-the-counter (OTC) business, after dietary supplements, analgesics and antacids.

This came even as the Dilip Shanghvi-promoted company launched its sunscreen brand "Suncros" through its global consumer healthcare business vertical with a target to garner a 30 per cent market share in the next two to three years.

Suncros was available only in the prescription segment till now. Sun Pharma has entered the consumer healthcare business with the acquisition of Ranbaxy, which had launched Suncros in 2005.

"Suncros has an 18 per cent market share and we are looking at a 30 per cent market share in two to three years," Abhay Gandhi, chief executive officer of Sun Pharma India business, said.

The total sunscreen market in India is estimated at Rs 380 crore and is growing at 25 per cent. Of the total market size, one-third is the prescription segment.

The drug major disclosed that the business division's entry into the dermatology category offered it a larger play into the fast-moving consumer goods category.

The company said OTC, or the consumer healthcare business, was a high-margin, high-growth business and the plan was to use it as a base to create a global consumer entity.